BioCentury
ARTICLE | Clinical News

5B1 antibody: Phase I started

August 8, 2016 7:00 AM UTC

MabVax began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate 3 mg IV MVT-2163 with or without 17 or 47 mg IV MVT-5873 in about 28 patients. MabVax’s MVT-2163 is a radiol...